REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
661.14 USD   +0.61%
05/21Evkeeza« (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $585 From $617, Maintains Equal Weight Rating

01/18/2022 | 01:02pm EDT


ę MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
05/21Evkeeza« (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with U..
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
05/17Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
PR
05/16Regeneron Pharmaceuticals, Inc. - HIGH SCHOOL SCIENTISTS FROM AROUND THE WORLD WIN NEAR..
AQ
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/10TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/05RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $658 From $647, Maintains..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 844 M - -
Net income 2022 4 040 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 17,8x
Yield 2022 -
Capitalization 71 235 M 71 235 M -
EV / Sales 2022 5,28x
EV / Sales 2023 4,79x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 661,14 $
Average target price 689,35 $
Spread / Average Target 4,27%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.4.69%71 235
GILEAD SCIENCES, INC.-12.08%80 075
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612
GENMAB A/S-17.26%20 205